A preliminary observation on rod cell photobiomodulation in treating diabetic macular edema

被引:7
作者
Chen, Zhiqing [1 ]
Chen, Binbin [1 ]
Hu, Peike [1 ]
Liu, Haipeng [2 ]
Zheng, Dingchang [2 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 2, Eye Ctr, Sch Med, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China
[2] Univ Coventry, Res Ctr Intelligent Healthcare, Coventry, England
来源
ADVANCES IN OPHTHALMOLOGY PRACTICE AND RESEARCH | 2022年 / 2卷 / 02期
关键词
Dark adaptation; Diabetic macular edema; Diabetic retinopathy; Photobiomodulation; Rod cells; RETINOPATHY; PREVENTION; PREVALENCE; SPARE; SPOIL;
D O I
10.1016/j.aopr.2022.100051
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To evaluate the safety and effectiveness of photobiomodulation (PBM) in the treatment of diabetic macular edema (DME). Methods: It was a single-center, self-controlled prospective study. The clinical records of 12 diabetic retinopathy patients (5 males and 7 females, 20 eyes in total) who were treated with PBM for DME at the Second Affiliated Hospital, Zhejiang University School of Medicine, were analyzed. The mean age was 56 (26-68) years. All the participants received PBM treatment during darkness at night in no less than 5 days per week and no less than 8 h per day. In the baseline check and follow-up checks (1, 2, 6, 10, and 12 months after the start of treatment), the best-corrected visual acuity, the thickness of the retina in the macula, and the changes of the fundus lesions were observed. Wilcoxon signed rank test was used to compare the results before and after treatment. P < 0.05 was considered statistically significant. Results: No fundus complication was observed during follow-up checks. In baseline and 12-month follow-up checks, the best-corrected visual acuity was 71.75 +/- 12.47 and 79.50 +/- 10.85, maximal retinal thickness in macular area was 390.95 +/- 77.12 mu m and 354.13 +/- 55.03 mu m, average retinal thickness in macular area was 334.25 +/- 36.45 mu m and 314.31 +/- 33.28 mu m, foveal thickness was 287.00 +/- 46.79 mu m and 265.63 +/- 67.14 mu m. The best-corrected visual acuity, average retinal thickness in macular area in consecutive follow-up results except that in the 1st month showed significant difference compared with baseline results. There were significant difference between every follow-up result and baseline result of maximal retinal thickness in macular area (P < 0.05). All follow-up results of foveal thickness were not significantly different (P > 0.05) from the baseline result, except that in the 6th month (P = 0.049). Obvious improvement could be observed in retinal fundus fluorescein angiography images. Conclusions: PBM is a safe and effective treatment of DME, which deserves further investigation.
引用
收藏
页数:6
相关论文
共 22 条
[11]   Effectiveness and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: A Real-World Experience [J].
Mello Filho, Paulo ;
Andrade, Gabriel ;
Maia, Andre ;
Maia, Mauricio ;
Biccas Neto, Laurentino ;
Muralha Neto, Acacio ;
Brasil, Oswaldo Moura ;
Minelli, Eduardo ;
Dalloul, Claudio ;
Iglicki, Matias .
OPHTHALMOLOGICA, 2019, 241 (01) :9-16
[12]  
Merry G, 2012, Investigative ophthalmology & visual science, V53, P2049
[13]   Photobiomodulation Therapy for Age-Related Macular Degeneration and Diabetic Retinopathy: A Review [J].
Muste, Justin C. ;
Russell, Matthew W. ;
Singh, Rishi P. .
CLINICAL OPHTHALMOLOGY, 2021, 15 :3709-3720
[14]   Preclinical and clinical studies of photobiomodulation therapy for macular oedema [J].
Shen, Weiyong ;
Teo, Kelvin Yi Chong ;
Wood, John P. M. ;
Vaze, Anagha ;
Chidlow, Glyn ;
Ao, Jack ;
Lee, So-Ra ;
Yam, Michelle X. ;
Cornish, Elisa E. ;
Fraser-Bell, Samantha ;
Casson, Robert J. ;
Gillies, Mark C. .
DIABETOLOGIA, 2020, 63 (09) :1900-1915
[15]   Spare the rods and spoil the retina: revisited [J].
Sivaprasad, S. ;
Arden, G. .
EYE, 2016, 30 (02) :189-192
[16]   Clinical efficacy and safety of a light mask for prevention of dark adaptation in treating and preventing progression of early diabetic macular oedema at 24 months (CLEOPATRA): a multicentre, phase 3, randomised controlled trial [J].
Sivaprasad, Sobha ;
Vasconcelos, Joana C. ;
Prevost, A. Toby ;
Holmes, Helen ;
Hykin, Philip ;
George, Sheena ;
Murphy, Caroline ;
Kelly, Joanna ;
Arden, Geoffrey B. .
LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (05) :382-391
[17]   A multicentre phase III randomised controlled single-masked clinical trial evaluating the clinical efficacy and safety of light-masks at preventing dark-adaptation in the treatment of early diabetic macular oedema (CLEOPATRA): study protocol for a randomised controlled trial [J].
Sivaprasad, Sobha ;
Arden, Geoffrey ;
Prevost, A. Toby ;
Crosby-Nwaobi, Roxanne ;
Holmes, Helen ;
Kelly, Joanna ;
Murphy, Caroline ;
Rubin, Gary ;
Vasconcelos, Joanna ;
Hykin, Philip .
TRIALS, 2014, 15
[18]   Prevalence, risk factors and burden of diabetic retinopathy in China: a systematic review and meta-analysis [J].
Song, Peige ;
Yu, Jinyue ;
Chan, Kit Yee ;
Theodoratou, Evropi ;
Rudan, Igor .
JOURNAL OF GLOBAL HEALTH, 2018, 8 (01)
[19]   Low-Intensity Far-Red Light Inhibits Early Lesions That Contribute to Diabetic Retinopathy: In Vivo and In Vitro [J].
Tang, Johnny ;
Du, Yunpeng ;
Lee, Chieh Allen ;
Talahalli, Ramaprasad ;
Eells, Janis T. ;
Kern, Timothy S. .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (05) :3681-3690
[20]   Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review [J].
Ting, Daniel Shu Wei ;
Cheung, Gemmy Chui Ming ;
Wong, Tien Yin .
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2016, 44 (04) :260-277